Cardiovascular adverse events of ICIs in patients with malignancies:Systematic review and meta-analysis
Objective:To systematically analyze the risk of cardiovascular adverse events in patients treated with immune checkpoint inhibitors(ICIs),a star in anti-tumor therapy.Methods:Researchers searched 4 databases for all randomized controlled trials about ICIs for cardiovascular adverse events.Data were pooled into a stratified meta-analysis and the odds ratio and its corresponding 95%confi-dence interval were calculated.Results:A total of 62 randomized controlled trials were included in the analysis.The all-grade cardiac adverse events and vascular adverse events of single ICIs were signifi-cantly different from that of the control group,and in particular,all grades or≥grade 3 of myocarditis were more significant.No other significant adverse events were shown in the ICIs group except for pericardial diseases.Conclusion:The results revealed that single ICIs could increase the risk of car-diovascular adverse events of all grades,especially myocarditis and pericardial diseases.Therefore,the patient's cardiovascular basis should be evaluated in detail before using ICIs.
NETL
NSTL
万方数据
